Journal of controlled release : official journal of the Controlled Release Society

Lipid nanoparticles that target lungs deliver SMAD7 mRNA to reduce lung scarring

Updated

Abstract

Engineered lung-targeting lipid nanoparticles achieved functional mRNA delivery in approximately 20% of specific mesenchymal cells in fibrotic lungs.

  • Fibroblast activation and differentiation into myofibroblasts contribute to excessive scarring in pulmonary fibrosis.
  • Therapeutic delivery of SMAD7 mRNA inhibited fibroblast activation in human lung fibroblast cultures.
  • In a preclinical model, treatment led to an approximately 40% reduction in histological collagen deposition.
  • There was a significant reduction in lung hydroxyproline content, indicating decreased fibrosis.
  • The vitronectin/vitronectin receptor axis may play a role in the uptake of the engineered lipid nanoparticles.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free